A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I-Reference-Cited by-同舟云学术

A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I

Published:2018-03 Issue: Volume:8 Page:42-51
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Le Steven Q.,Kan Shih-hsin,Clarke Don,Sanghez Valentina,Egeland Martin,Vondrak Kristen N.,Doherty Terence M.,Vera Moin U.,Iacovino Michelina,Cooper Jonathan D.,Sands Mark S.,Dickson Patricia I.

Funder

Eunice Kennedy Shriver Institute for Child Health and Human Development

National Institute for Neurological Disorders and Stroke

NIH

American Heart Association

Los Angeles Biomedical Research Institute and the Department of Pediatrics at Harbor-UCLA Medical Center

UCLA Medical Genetics Training Program

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference25 articles.

1. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT;Banugaria;PLoS One,2013

2. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease;Elder;J. Pediatr.,2013

3. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I;Giugliani;Mol. Genet. Metab.,2009

4. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment;Wang;Nat. Biotechnol.,2008

5. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I;Dickson;J. Clin. Invest.,2008

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opportunities for nanomaterials in enzyme therapy;Journal of Controlled Release;2024-08

2. Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs;Journal of Controlled Release;2024-05

3. Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I;Molecular Genetics and Metabolism Reports;2024-03

4. Intra-Articular AAV9 α-l-Iduronidase Gene Replacement in the Canine Model of Mucopolysaccharidosis Type I;Advances in Cell and Gene Therapy;2023-09-14

5. Clinical and pathological characterization of ophthalmic disease in a canine model of mucopolysaccharidosis type I;Journal of Inherited Metabolic Disease;2023-01-16